SG Americas Securities LLC Boosts Stake in Corcept Therapeutics Incorporated (NASDAQ:CORT)

SG Americas Securities LLC lifted its holdings in Corcept Therapeutics Incorporated (NASDAQ:CORTFree Report) by 262.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,663 shares of the biotechnology company’s stock after buying an additional 21,479 shares during the quarter. SG Americas Securities LLC’s holdings in Corcept Therapeutics were worth $1,373,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the business. Nisa Investment Advisors LLC boosted its stake in shares of Corcept Therapeutics by 10.5% in the second quarter. Nisa Investment Advisors LLC now owns 5,368 shares of the biotechnology company’s stock valued at $174,000 after buying an additional 510 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its stake in shares of Corcept Therapeutics by 0.4% in the second quarter. Allspring Global Investments Holdings LLC now owns 127,348 shares of the biotechnology company’s stock valued at $4,138,000 after buying an additional 541 shares in the last quarter. GAMMA Investing LLC boosted its stake in shares of Corcept Therapeutics by 90.6% in the first quarter. GAMMA Investing LLC now owns 1,218 shares of the biotechnology company’s stock valued at $31,000 after buying an additional 579 shares in the last quarter. Bank of Montreal Can boosted its stake in shares of Corcept Therapeutics by 5.0% in the second quarter. Bank of Montreal Can now owns 12,156 shares of the biotechnology company’s stock valued at $395,000 after buying an additional 580 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its stake in shares of Corcept Therapeutics by 1.9% in the second quarter. The Manufacturers Life Insurance Company now owns 48,780 shares of the biotechnology company’s stock valued at $1,585,000 after buying an additional 932 shares in the last quarter. 93.61% of the stock is currently owned by hedge funds and other institutional investors.

Corcept Therapeutics Stock Up 0.3 %

NASDAQ CORT opened at $45.94 on Thursday. Corcept Therapeutics Incorporated has a fifty-two week low of $20.84 and a fifty-two week high of $47.71. The stock has a market cap of $4.78 billion, a price-to-earnings ratio of 43.34 and a beta of 0.46. The business has a fifty day moving average of $38.00 and a 200-day moving average of $31.93.

Corcept Therapeutics (NASDAQ:CORTGet Free Report) last released its quarterly earnings results on Monday, July 29th. The biotechnology company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.23 by $0.09. Corcept Therapeutics had a return on equity of 23.66% and a net margin of 21.93%. The company had revenue of $163.80 million during the quarter, compared to analysts’ expectations of $155.14 million. During the same period in the previous year, the firm posted $0.25 earnings per share. The business’s revenue for the quarter was up 39.1% compared to the same quarter last year. As a group, analysts anticipate that Corcept Therapeutics Incorporated will post 1.12 EPS for the current year.

Insider Transactions at Corcept Therapeutics

In related news, insider Gary Charles Robb sold 11,000 shares of the company’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $46.28, for a total value of $509,080.00. Following the completion of the transaction, the insider now directly owns 22,772 shares in the company, valued at approximately $1,053,888.16. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, insider William Guyer sold 10,000 shares of Corcept Therapeutics stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $35.30, for a total value of $353,000.00. Following the transaction, the insider now owns 6,039 shares in the company, valued at approximately $213,176.70. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Gary Charles Robb sold 11,000 shares of the company’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $46.28, for a total value of $509,080.00. Following the sale, the insider now owns 22,772 shares of the company’s stock, valued at $1,053,888.16. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 34,251 shares of company stock valued at $1,365,292 over the last three months. 20.50% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

CORT has been the subject of several research reports. Piper Sandler lifted their price objective on Corcept Therapeutics from $38.00 to $67.00 and gave the stock an “overweight” rating in a report on Wednesday, September 18th. HC Wainwright lifted their price objective on Corcept Therapeutics from $40.00 to $45.00 and gave the stock a “buy” rating in a report on Tuesday, July 30th. Truist Financial lifted their price objective on Corcept Therapeutics from $65.00 to $76.00 and gave the stock a “buy” rating in a report on Monday, September 30th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $38.00 price objective on shares of Corcept Therapeutics in a report on Tuesday, July 30th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, Corcept Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $56.50.

Check Out Our Latest Stock Report on CORT

Corcept Therapeutics Company Profile

(Free Report)

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.

See Also

Institutional Ownership by Quarter for Corcept Therapeutics (NASDAQ:CORT)

Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.